Share on StockTwits

Vical (NASDAQ:VICL) CEO Vijay B. Samant sold 4,737 shares of the company’s stock on the open market in a transaction dated Monday, July 14th. The stock was sold at an average price of $1.17, for a total transaction of $5,542.29. Following the completion of the transaction, the chief executive officer now directly owns 941,251 shares in the company, valued at approximately $1,101,264. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Vical (NASDAQ:VICL) opened at 1.21 on Thursday. Vical has a 1-year low of $1.01 and a 1-year high of $4.51. The stock has a 50-day moving average of $1.19 and a 200-day moving average of $1.29. The company’s market cap is $105.1 million.

Vical (NASDAQ:VICL) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.60 million. During the same quarter last year, the company posted ($0.11) earnings per share. Vical’s revenue was up 50.0% compared to the same quarter last year. On average, analysts predict that Vical will post $-0.17 earnings per share for the current fiscal year.

Separately, analysts at Zacks upgraded shares of Vical from a “neutral” rating to an “outperform” rating in a research note on Tuesday, June 24th. They now have a $1.30 price target on the stock. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Vical currently has a consensus rating of “Hold” and a consensus price target of $1.93.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (NASDAQ:VICL) delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.